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Blood pressure reduction with HMG-CoA reductase inhibitors diovascular mortality in the general [1, 2] and end-stage
in renal transplant recipients. renal disease (ESRD) [3] populations. Renal transplant
Background. Besides lowering lipid levels, 3-hydroxy-3- recipients are also distinctly at high risk for developingmethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors
cardiovascular disease, due in part to factors that are(statins) modulate endothelial function and decrease vascular
likely to include hyperlipidemia [4]. As a result, statinstone. The effect of statin therapy on blood pressure has not
been previously examined in renal transplant recipients. have been administered to renal transplant recipients
Methods. We identified 113 stable recipients with graft sur- [5, 6] and found to be reasonably safe and effective as
vival 1 year and started on a statin 1 year post-transplant
lipid-lowering agents. In addition, they have a favorablewith no subsequent alteration in type or dose, as well as 6
effect on chronic and acute allograft rejection [7, 8].months’ follow-up post-statin introduction along with no changes
in antihypertensive medication type or dosage. This “statin” Statins provide other benefits, particularly on the vas-
group was compared to a control group matched 1:1 by age, culature [9]. They increase small blood vessel elasticity
gender, donor source, year of transplant, and time since trans- [10], improve endothelial function [11], and decrease
plant who met identical criteria but were not begun on a statin.
vascular responsiveness to angiotensin II [12]. Moreover,Baseline, 6 months, and 12 months outpatient blood pressure
measurable decrements in blood pressure have beenwere reviewed and compared along with other possible blood
pressure predictors. A multivariate analysis was performed noted in small numbers of normotensive [10], hyperten-
controlling for other influences on blood pressure change. sive [13, 14], and diabetic [15] individuals treated with
Results. Blood pressure and baseline characteristics other statins. Since hypertension is highly prevalent in renalthan lipid levels were similar in the two groups. The systolic, dia-
transplant recipients, and the underlying mechanismsstolic, and mean arterial blood pressure decreased by 7 mm Hg
(P  0.005), 3 mm Hg (P  0.05), and 4 mm Hg (P  0.007), may differ from the general population, we sought to
respectively, at 12 months’ post-statin introduction, while no determine if statin therapy alters blood pressure in this
blood pressure change was seen in the control group (PNS). group of patients. Such an effect if present would have
At 12 months, the systolic, diastolic, and mean arterial blood
important implications in managing cardiovascular dis-pressures were lower in the statin group compared to the con-
ease risk factors in renal transplant recipients.trol group (P 0.05, 0.03, and 0.02, respectively). These changes
in blood pressure were independent of changes in serum lipid
levels.
Conclusion. Renal transplant recipients exhibit a significant METHODS
blood pressure reduction associated with statin therapy. This The nephrology clinic at our institution provides post-finding has important mechanistic and clinical implications in
transplant care to approximately 700 adult single-organthe management of cardiovascular disease risk factors in this
renal transplant recipients. The records of this popula-population.
tion were reviewed in order to identify individuals with
graft survival 1 year, stable renal function as defined
Treatment of hyperlipidemia with 3-hydroxy-3 meth- by no episodes of acute rejection and fluctuation of the
ylglutaryl-coenzyme A (HMG-CoA) reductase inhibi- serum creatinine limited to 10% over the preceding
tors (“statins”) has been shown to reduce total and car- 6 months, and who were started on statin therapy 1
year post-transplant. For inclusion in the study, patients
also required6 months’ follow-up post-statin introduc-Key words: HMG-CoA reductase inhibitors, statins, post-transplant
hypertension, blood pressure, hyperlipidemia. tion, as well as no subsequent alteration in statin or anti-
hypertensive medication type or dosage. Patients wereReceived for publication March 18, 2002
also excluded if they were known to have received ther-and in revised form July 11, 2002
Accepted for publication September 4, 2002 apy with a statin or other lipid-lowering agent (e.g., fi-
brate) prior to transplantation or within the first post- 2003 by the International Society of Nephrology
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Table 1. Demographic characteristics of the study population Univariate comparisons were made within each group
and between groups using unpaired Student t test, re-Statin group Control group
Parameter (N  113) (N  113) P value peated-measures ANOVA, or chi-square analysis as ap-
propriate. Multivariate analysis for the change in bloodAge at transplantation
years 43.510 43.211 0.84 pressure associated with statin therapy included pre-
Age at starting statin/ dictors of post-transplant hypertension with univariatefirst blood pressure
significance 0.25. Correction for multiple comparisonsmeasurement 49.411 49.011 0.77
Gender M/F 65/48 65/48 1.00 was made using the Bonferroni method. All data are
Donor source live/cadaver 33/80 33/80 1.00 reported as mean  SD unless otherwise specified, andPrimary/secondary
for all associations a two-tailed P value0.05 was consid-transplant 110/3 110/3 1.00
No. of blood pressure ered significant. SAS and SPSS software were used
medications 1.730.9 1.731 1.00 for all the analyses. The Research Ethics Board at St.Cause of ESRD
Michael’s Hospital approved the protocol for this study.Diabetes mellitus 6 10 0.84
Hypertension 8 9
Glomerulonephritis 52 49
ADPKD 14 13 RESULTS
Others 33 32
From 260 of 702 current renal transplant recipients in
Abbreviations are: ESRD, end-stage renal disease; ADPKD, autosomal domi- our clinic with a history of statin or other lipid-loweringnant polycystic kidney disease.
drug therapy, 113 met the entry criteria for the study.
Their baseline demographic characteristics, along with
those of the 1:1 matched controls selected from the 442transplant year, or if their antihypertensive medications
of 702 patients with no history of statin or other lipid-were altered within 3 months prior to statin introduction.
lowering drug exposure, are shown in Table 1. All ofThis “statin” group was compared to a control group
the patients were transplanted between March 1975 andmatched 1:1 by age, gender, donor source, year of trans-
November 2000. In the statin group, 91 patients receivedplant, and time since transplant who met identical inclu-
cyclosporine while seven received tacrolimus. In the con-sion and exclusion criteria but were never begun on a
trol group, 100 received cyclosporine while five receivedstatin or other lipid-lowering agent.
tacrolimus (P  NS). There was no crossover in calci-In the clinic, blood pressure is measured in a standard-
neurin-inhibitor type during the follow-up period. Amongized manner using a calibrated mercury sphygmoma-
the statin group, 62 received atorvastatin, 41 receivednometer, with the patient sitting for at least 5 minutes
pravastatin, nine were given simvastatin, and one wasprior to measurement. In the selected cohort, in order to
given fluvastatin. In the statin group, 94% of patientsassess the stability of blood pressure prior to statin ther-
and 92% of patients in the control group were on atapy, the blood pressure value 6 months prior to statin
least one antihypertensive drug (P  NS). There wereinitiation (6 months) was recorded for the statin group,
also no differences in types of antihypertensive drugs used.along with the corresponding6-month value in the con-
There were no differences in blood pressure betweentrol group. Baseline (0 month), 6 months, and 12 months
the groups at –6 months (134.3  15 mm Hg systolic,outpatient blood pressure were reviewed along with
83.4  9 mm Hg diastolic in the statin group; 133.7 other possible predictors of blood pressure, including
14 mm Hg systolic, 83.4 9 mm Hg diastolic in the controlserum creatinine, hemoglobin, weight, immunosuppres-
group). There was also no difference in either group be-sive drug dosage/levels, antihypertensive drug profile,
tween the –6 month and baseline blood pressures (P 
and fasting lipid levels at each time point. The 6- and NS). Table 2 provides the systolic, diastolic, and mean
12-month intervals were selected because stable renal arterial pressures of the two groups at baseline (0 months),
transplant recipients return to the clinic once every 6 months, and 12 months post-statin introduction. Within
6 months after the first post-transplant year. A subgroup the statin group, the systolic and diastolic pressures were
analysis of blood pressure changes seen in the statin and lower at 6 months and 12 months compared to baseline,
control groups of patients based on type of calcineurin- although the difference at 6 months was not significant
inhibitor (cyclosporine or tacrolimus), as well as type of for either (P  NS). Within the control group, on the
antihypertensive agent [angiotensin-converting enzyme other hand, there was no change in either systolic or dia-
(ACE) inhibitors and/or calcium channel blockers], was stolic blood pressure at 6 or 12 months. While there was
also performed. Finally, in order to test the validity of no difference in blood pressure between the two groups
any blood pressure changes found in a less-selective at baseline, by 12 months, the systolic and diastolic pres-
transplant population, we separately evaluated these sures were significantly lower in the statin group.
changes in a different set of patients whose antihyperten- There were no significant differences at baseline be-
sive medication or statin type or dose had been changed tween the two groups except for fasting total choleste-
rol and triglyceride levels, which were higher in the sta-during the follow-up period.
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Table 2. Change in blood pressure over 12 months in the statin and control groups
P value
Blood pressure parameter Month Month 0 Month 6a Month 12a (Month 0 vs. 12)
Systolic blood pressure mm Hg Statin 135.016 131.018 128.315 0.005
Control 133.914 132.817 133.117 NS
P value NS NS 0.05
Diastolic blood pressure mm Hg Statin 82.510 80.19 79.49 0.05
Control 83.98 81.910 82.510 NS
P value NS NS 0.03
Mean arterial pressure mm Hg Statin 100.010 97.110 95.710 0.007
Control 100.69 98.811 99.411 NS
P value NS NS 0.02
NS is not significant.
a Actual followup times were 6.0  1 and 12.3  1 months in the statin group and 6.0  1 and 12.1  2 months in the control group.
Table 3. Change in other parameters in the statin and control groups over time
Statin group (N  113) Control group (N  113)
P value P value
0 6 12 (0 vs. 12) 0 6 12 (0 vs. 12)
Months Months Months Months Months Months Months Months
Creatinine lmol/L 13142 13242 13143 1.00 13454 14157 14467 0.14
Hemoglobin g/dL 13820 135.818 13818 0.30 13418 13419 13420 1.00
Weight kg 76.220 77.519 77.919 1.00 73.116 74.118 75.220 0.55
CsA dose mg/day 22071 21869 21268 0.05 221.581 22180 21577 0.002
CsA level ng/mL 17868 18264 16854 1.00 15063 15474 13956 0.63
Tac dose mg/day 5.83 5.63 5.33 0.61 51 51 41 1.00
Tac level ng/mL 100.7 7.42 6.21 0.17 8.81 11.342 8.21 1.00
Prednisone dose mg/day 7.51 7.41 7.21 0.12 7.52 7.42 7.22 0.10
Abbreviations are: CsA, cyclosporine A; tac, tacrolimus.
tin group than the control group (6.94  1 vs. 5.32  predictors of change in systolic and diastolic blood pres-
1 mmol/L and 2.88 1 vs. 1.78 1 mmol/L, respectively). sure at 12 months. The effect of statin use was indepen-
Fasting total cholesterol and triglyceride levels were dent of the change in fasting cholesterol or triglyceride
significantly reduced at 6 months (5.58  1 mmol/L, levels, level of renal function, and calcineurin-inhibitor
2.42  1.3 mmol/L, respectively) and 12 months (5.26  dosage or level.
1 mmol/L, 2.17  1.3 mmol/L, respectively) compared In subgroup analyses, blood pressure changes, as well
to baseline in the statin group but remained unchanged as differences between the statin and control groups,
in the control group (5.50  0.8 mmol/L, 1.68  0.7 were similar in the cyclosporine-treated patients (N 
mmol/L at 6 months; 5.41 1 mmol/L, 1.78 0.8 mmol/L 91 and 100, respectively) compared to the entire group,
at 12 months). In addition, lipid levels were no longer while the number of tacrolimus-treated patients was in-
different between the statin and control groups at 6 or sufficient (N  7 and 5, respectively) for meaningful
12 months. Table 3 provides values for other potential interpretation. Likewise, within group blood pressure
predictors of blood pressure at each time point (baseline, changes, as well as differences between the statin and
6 months, and 12 months). The cyclosporine A (CsA)
control groups, were similar in the ACE inhibitor (N 
dosage was significantly lower in the statin and control
55 and 37, respectively), calcium channel blocker (N groups at 12 months compared to baseline. However,
75 and 70, respectively), and combined therapy (N  29the trough CsA level at 12 months was higher in the
and 23, respectively) subgroups compared to the entirestatin group compared to the control group (168 ng/mL
group (P NS for each). Finally, 147 of the 260 patientsvs.139 ng/mL, P 0.01). There were no other differences
who had received statins in our clinic were ineligible forin each of the groups at 6 or 12 months compared to
the study. Of these, 86 patients were excluded from thebaseline, or between groups at 6 or 12 months (PNS).
primary study because of change in antihypertensive orAlthough univariate analysis for the change in blood
statin type or dose during the follow-up period. In thispressure demonstrated the CsA level (P  0.06) and
excluded subgroup, there was neither a change in bloodtriglyceride level (P  0.06) to be possible predictors,
pressure from baseline to 6 months or 12 months nor athe multivariate analysis revealed only the use of statins
difference between the statin and control groups at each(P 0.02), baseline level of blood pressure (P 0.0001),
and prednisone dose (P  0.001) to be independent point in time.
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None of the patients who received statins experienced This is the first study to demonstrate significant blood
pressure changes associated with statin therapy in stableany significant side effects attributable to therapy.
renal transplant recipients. The natural history of hyper-
tension in hyperlipidemic transplant recipients is not
DISCUSSION known, but in our patients the blood pressure was stable
In this study we have shown that the prescription of during the 6 months prior to statin initiation. It is possi-
statin therapy to stable renal transplant recipients is asso- ble, however, that the blood pressure in these patients
ciated with long-term reduction in systolic, diastolic, and may have increased over time without statin therapy.
mean arterial blood pressure. This effect is independent A previous evaluation of fluvastatin administered early
of a reduction in serum lipid levels, as well as other post-transplant did not detect a change in blood pressure
predictors of post-transplant hypertension. over 12 weeks [24]. By comparison, our own cohort was
The effect of statins in transplant recipients has been further past the date of transplantation and a blood pres-
a focus of attention in recent years. Statins reduce the sure decline was noted by 6 months’ post-statin introduc-
synthesis of biologically active isoprenoid intermediates tion, although this attained significance only by 12 months
in the mevalonate pathway of cholesterol biosynthesis (Table 3). This suggests that the vascular effects of statins
[16]. Resultant effects include increased plasma nitric in renal transplant recipients may be more long-term
oxide levels and improved endothelial function [11], as and slower to accomplish than in non-transplanted [10,
well as reduced activation, proliferation, and cytotoxicity 13, 14] individuals. This effect may also be undetectable
of T lymphocytes and natural killer cells [7, 8, 17, 18]. in the early post-transplant period, possibly due to other
In non-transplant populations, statins inhibit vascular factors such as higher calcineurin inhibitor and steroid
smooth muscle cell proliferation [9], and also inhibit doses. Interestingly, in this study a lower blood pressure
platelet-derived growth factor-induced macrophage and was noted in the statin group despite higher CsA levels
platelet migration and activation [9]. Statins also inhibit when compared to the control group, which may have
the oxidation of low-density lipoprotein cholesterol, been due to a statin-cyclosporine interaction and which
thereby decreasing monocyte adhesion to the endothe- one might expect would have resulted in an increase in
lium and reducing macrophage cholesterol uptake [19]. blood pressure instead. Although a prospective evalua-
They also decrease vascular reactivity to norepinephrine tion of long-term cardiovascular effects associated with
and angiotensin II [20], and downregulate AT1 recep- statins is awaited [25], it is tempting to propose that the
tors, decreasing aldosterone levels [21]. At a clinical level, blood pressure-reducing effect of statins may be benefi-
an average drop in systolic blood pressure of 6 mm Hg cial in this context.
and diastolic blood pressure of 3 mm Hg was noted in The limitations of this study must be mentioned. We
17 hypercholesterolemic but normotensive individuals have demonstrated an association between statin use and
after 20 weeks of therapy with atorvastatin [10]. Declines lowered blood pressure in renal transplant recipients;
of 11 mm Hg systolic and 10 mm Hg diastolic were noted insight into possible mechanisms behind this association
in a group of 41 hypercholesterolemic but hypertensive requires pharmacodynamic evaluation. We did not have
individuals after 3 months of treatment with pravastatin sufficient statistical power to assess the effects of individ-
or simvastatin [14]. A large retrospective review, the ual statins, nor did we have a sufficient number of high-
Brisighella Heart Study, reported by Borghi et al, density lipoprotein or low-density lipoprotein measure-
showed that blood pressure decrements are more promi- ments to perform a meaningful analysis of their influ-
ence. It should also be emphasized that these patientsnent in patients with higher starting blood pressure levels
were stable in many respects (prior blood pressure con-[22]. Statins also blunt the hypertensive response to the
trol, renal function, immunosuppression, and relativelycold pressor test [23]. The magnitude of blood pressure
low rate of diabetes). Consequently, the blood pressure-changes seen in most studies [21] is compatible with our
lowering effect of statins may not be apparent in lessown findings, which were 7 mm Hg systolic and 3
stable patients. A prospective study to address thesemm Hg diastolic over 12 months (Table 2), even with
issues is warranted.minimal doses of statins in the majority of patients. It
has been suggested that the effects of statins on blood
Conclusionpressure may be more pronounced in non-transplanted
individuals receiving therapy with either calcium channel We have shown that the use of statins in stable renal
transplant recipients is associated with a reduction inblockers or ACE inhibitors [21], which are two classes of
drugs widely used to treat post-transplant hypertension. their blood pressure, independent of their influence on
lipid levels. This finding may carry important implica-However, there was no difference in the statin-associated
blood pressure change associated with either class of tions for the long-term management of cardiovascular
disease risk factors in this population.antihypertensive agent in this study.
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